LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

NCT00593047 | Completed Phase 2 DMC

• 2 other identifiers: KBT0042007-004413-33
• Study Type: interventional
• Target: 180
• Locations: 1 country
• Sites: 1

Brief Summary

Thyroid hormones are known to reduce cholesterol levels through regulation of a number of key enzymes involved in synthesis, degradation, and lipid transport. However, the currently marketed thyroid agonists are non-selective, and cannot be used for the treatment of hypercholesterolemia due to extrahepatic consequences of hyperthyroidism, especially on heart, bone, and muscle. To take advantage of thyroid hormone effect on lipid metabolism for the treatment of hypercholesterolemia, it is necessary to develop a selective thyroid receptor agonist that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue. KB2115 is a thyroid agonist developed to be liver selective. The purpose of the study is to assess the efficacy and safety of KB2115 as add on therapy to low and middle doses of statin following 12 weeks of exposure compared to placebo. The aim of the study is to assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115 at doses between 25 and 100 µg and to define a clinically relevant dose or dose range for future studies.

Conditions

Dyslipidemia

Keywords

hypercholesterolemia

Outcome Measures

Primary Outcomes (1)

• LDL cholesterol

  12 weeks

Secondary Outcomes (1)

• Triglyceride

  12 weeks

Study Arms (4)

1

PLACEBO COMPARATOR

Statin + placebo

Drug: KB2115

2

EXPERIMENTAL

Statin + KB2115 dose 1

Drug: KB2115

3

EXPERIMENTAL

Statin + KB2115 dose 2

Drug: KB2115

4

EXPERIMENTAL

Statin + KB2115 dose 3

Drug: KB2115

Interventions

KB2115 DRUG

tablet formulation given once daily for 12 weeks

1; 2; 3; 4

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent
• Males or females aged 18 to 75 years. Female patients must be non-fertile. To be considered as non-fertile, females must fulfil the following:
• Non-nursing and non-pregnant 12 months prior to enrolment
• Not of child bearing potential ie, either documented irreversible surgically sterile (bilateral oophorectomy or hysterectomy is acceptable, but not tubal ligation) or post-menopausal. Post-menopausal is defined as serum follicle-stimulating hormone (FSH) levels in the post-menopausal range combined with amenorrhea for more than 1 year in a woman above 50 years of age, or amenorrhea for more than 2 years below 50 years of age
• Patients with hypercholesterolemia treated with stable doses of the below listed lipid lowering medication for at least 3 months prior to randomization
• Atorvastatin not more than 20 mg/day or
• Simvastatin not more than 40 mg/day
• LDL-cholesterol \> 3.0 mmol/L (Week -1)
• Subject able and willing to comply with all study requirements
• At randomization, diet as instructed by the investigator during the last 4 weeks prior to randomization and willingness to follow these instructions throughout the study

You may not qualify if:

• Cholesterol lowering agents other than the defined statins
• History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the investigator
• Clinically significant illness or clinically relevant trauma within 2 weeks before the administration of the investigational product as judged by the investigator
• Chronic (\> 3 months) pain condition requiring daily medication with pain killers
• Glycosylated haemoglobin (HbA1c) \> 7.0%
• Diabetes requiring medication other than metformin
• Clinically abnormal physical findings and laboratory values as judged by the investigator and abnormal resting ECG, eg, QTc interval \> 450 msec
• Body Mass Index of ≥ 40 kg/m2
• Resent history (\< 3 month) of stroke or transient ischemic attacks
• History of seizure disorder, except febrile convulsions
• A current diagnosis of cancer, unless in remission
• Blood pressure (BP) of \> 160/95 mm Hg
• History of cardiac arrhythmia, such as intermittent supraventricular tachyarrhythmia and atrial fibrillation
• Unstable angina pectoris, myocardial infarction or coronary bypass graft surgery or percutaneous coronary intervention \< 6 month before randomization
• Congestive heart failure New York Heart Association Class \> 2

Sponsors & Collaborators

• Karo Bio AB: lead

Study Sites (1)

Carl-Peter Anderberg

Gothemburg, Sweden

Location

Related Publications (1)

• Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010 Mar 11;362(10):906-16. doi: 10.1056/NEJMoa0905633.

  PMID: 20220185 DERIVED

MeSH Terms

Conditions

Dyslipidemias; Hypercholesterolemia

Interventions

3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Hyperlipidemias

Study Officials

• Jens Kristensen, MD, PhD

  Karo Bio AB

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: December 17, 2007
• First Posted: January 14, 2008
• Study Start: November 1, 2007
• Primary Completion: July 1, 2008
• Study Completion: September 1, 2008
• Last Updated: December 1, 2008

Record last verified: 2008-05

Locations

SE (1)